Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange:600276.SS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

China

Market Cap

USD 48.41 B

Share Price

USD 7.29

Avg Daily Volume

50,348,784

Change (1 day)

-1.15%

Change (1 year)

32.80%

Change (YTD)

15.99%

Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities for the year ending December 31, 2024: USD 554.06 M

Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities is USD 554.06 M for the year ending December 31, 2024, a 42.97% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities for the year ending December 31, 2023 was USD 387.54 M, a -32.16% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities for the year ending December 31, 2022 was USD 571.21 M, a -1.76% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities for the year ending December 31, 2021 was USD 581.43 M, a -3.74% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Total Liabilities for the year ending December 31, 2020 was USD 604.00 M, a 60.60% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Piao Yang Sun
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	20,238
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.